Navigation Links
Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
Date:7/29/2014

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Abide Therapeutics announced today the appointment of Nancy Thornberry to its board of directors. Thornberry was previously senior vice president and franchise head, Diabetes and Endocrinology for Merck & Co. Inc., where she led discovery, clinical research, strategy and overall pipeline management in diabetes, osteoporosis, fertility and contraception. Thornberry, a distinguished pharmaceutical scientist, initiated and co-led the program that resulted in the discovery of JanuviaTM, an inhibitor of DPP-4, a serine hydrolase, for the treatment of type 2 diabetes. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.

"Nancy has been an invaluable member of our scientific advisory board," said Alan Ezekowitz, MBChB, D.Phil., president and CEO of Abide Therapeutics. "As we advance our programs into the clinic, Nancy's in-depth knowledge of drug discovery and development will be invaluable. Additionally, her expertise in the serine hydrolase space will be advantageous in advising the Company on target selection and validation."

"As a member of Abide's scientific advisory board for the past year, I have seen firsthand the potential of Abide's disruptive technologies and the talent of the Company's team," said Thornberry. "As many know, DPP-4 is a member of the serine hydrolase family and inhibitors of this enzyme have proven to be important in the treatment of type 2 diabetes. With more than 200 members, the serine hydrolase family is involved in many key aspects of human physiology and disease. As a member of the board of directors, I look forward to helping Abide reach the full potential of their unique and powerful approach to target a validated but largely underexplored class of enzymes."

Nancy Thornberry began her long and distinguished career at Merck Research Laboratories (MRL) in 1979 as a biochemist. Among her most notable accomplishments are the identification of the first caspase, interleukin-1B converting enzyme (ICE/caspase-1), and development of a novel approach for the analysis of protease specificities. In 1999, she initiated the dipeptidyl peptidase 4 (DPP-4) program and co-led the team that led to the discovery of Januvia (sitagliptin). In 2007, Thornberry became a vice president and Worldwide Basic Research Head for Diabetes and Obesity, and was promoted in 2009 to SVP and franchise head of Diabetes and Obesity. In 2011, Thornberry became SVP and franchise head of Diabetes and Endocrinology. She has been an author on numerous publications and received a number of awards for her accomplishments, including the PhRMA's Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. 

About Serine Hydrolases

The large family of serine hydrolases are validated but largely underexplored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases. The technology provides a rapid and effective method for target identification and validation. 

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas. Abide is located in San Diego. To learn more, visit www.abidetx.com


'/>"/>
SOURCE Abide Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
2. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):